Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.
配体激活的 EGFR/MAPK 信号通路(而非 PI3K)是结直肠癌中 EGFR 疗法产生耐药性的关键机制
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-59588-3
Qu Xueping, Hamidi Habib, Johnson Radia M, Sokol Ethan S, Lin Eva, Eng Cathy, Kim Tae Won, Bendell Johanna, Sivakumar Smruthy, Kaplan Benjamin, de Sousa E Melo Felipe, Mancini Andrew, Wongchenko Matthew, Shi Yi, Shames David, Yan Yibing, Ciardiello Fortunato, Bais Carlos